Vaccine (DNA plasmid) · Immune activation, directed at Ebola virus glycoprotein · developed by INOVIO PHARMACEUTICALS
INO-4202 is a plasmid DNA vaccine delivered intramuscularly followed by electroporation. It is studied as a vaccine for Ebola virus infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02464670 | Phase 1 | Ebola Vaccine | Completed | INO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ebola Vaccine
Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.
See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INO catalysts and pipeline →